Articles tagged with Stem Cell Lines
Researchers used human embryonic stem cells to study myotonic dystrophy type 1, revealing reduced expression of SLITRK genes in affected brains. The findings highlight the potential of embryonic stem cells for understanding complex diseases like muscular dystrophy.
Tuft cells are a rare fifth type of intestinal cell with distinct features and a novel protein signature. They secrete opioids and produce enzymes that synthesize prostaglandins, suggesting potential roles in inflammation and tumorigenesis.
A new diagnostic test called PluriTest enables researchers to determine the quality of pluripotent stem cell lines with remarkable sensitivity and specificity. The test uses a detailed molecular model of normal pluripotent cells to identify genomic aberrations, alerting scientists to perform additional analysis.
Researchers discovered protein-coding point mutations in all 22 hiPSC lines, with an estimated six mutations per exome. The findings suggest that genetic screening of hiPSCs before clinical use is crucial to ensure their safety and accuracy.
Researchers found genetic rearrangements and 'copy number variations' associated with reprogramming adult cells to induced pluripotent stem cells. The study highlights the need for rigorous characterization of generated iPS lines to ensure genomic integrity.
A new method allows for quick and comprehensive characterization of induced pluripotent stem cells (iPS) and embryonic stem cell lines, enabling high-throughput assessment of quality and differentiation efficiency. The approach yields genome-wide reference maps detailing epigenetic and gene expression landscapes.
A new study reveals that mesenchymal stromal cells from wisdom teeth can be reprogrammed into stem cells, offering a potential source of treatment for patients. The cells displayed varying degrees of robustness and proliferated up to 100 times more efficiently than typical skin-cell-derived iPS cells.
Researchers have developed a method to convert human induced pluripotent stem (iPS) and embryonic stem (ES) cells to a more flexible state, similar to mouse ES cells. This breakthrough could improve the efficiency of gene targeting and potentially lead to new therapeutic applications for human ES and iPS cells.
Researchers have identified a cluster of small RNA that correlates with pluripotency in induced-pluripotent stem cells, enabling the distinction of more viable cell lines. This discovery is expected to improve the production of full pluripotent iPS cells and their application in disease therapy.
The Rutgers Stem Cell Research Center has derived new human embryonic stem cell lines, addressing concerns of contamination in previously approved lines. The center also offers a training course for stem cell scientists, with over 100 trained researchers to date.
US government's lifting of restrictions on federally-funded stem cell research has helped scientists focus on science, but limitations remain. George Daley will discuss the current climate and potential of induced pluripotent stem cells (iPS) in treating devastating diseases.
The Coriell Institute for Medical Research will enhance its collection of carefully maintained human cell lines by adding induced pluripotent stem (iPS) cells carrying disease gene mutations. The addition will enable scientists to study a wide range of diseases and make the repository an even more valuable resource.
Researchers have developed an efficient way to genetically modify human embryonic stem cells using bacterial artificial chromosomes, which can increase the yield by up to 20%. This approach enables the rapid development of stem cell lines that can serve as models for human genetic diseases and testbeds for potential treatments.
University of Michigan researchers have successfully induced embryonic stem cells to differentiate into parathyroid cells producing a hormone essential for maintaining bone density. The goal is to prevent osteomalacia, a severe form of bone loss affecting tens of thousands in the US.
Only two human embryonic stem cell lines, H1 and H9, have been used routinely in research, with the majority of requests coming from these lines. This finding raises concerns about the impact on future research and the need for a more diverse range of cell lines.
Researchers found distinct gene expression signatures in embryonic stem cells and induced pluripotent stem (iPS) cells, indicating they are not perfectly similar despite sharing potential to become all body tissues. The study aims to understand the biological significance of these differences and their impact on iPS cell function.
Scientists have successfully reprogrammed blood cells into cells that mimic embryonic stem cells, opening up new avenues for research and potential treatment of diseases. The discovery provides an accessible source of stem cells, which can be used to study various diseases and develop new therapies.
Researchers successfully reprogrammed cells from patients with difficult-to-study diseases, creating 'stem-cell-like' cells that can be induced to assume new identities. This innovation holds promise for understanding disease development and potentially treating conditions like Parkinson's disease and type 1 diabetes.
Researchers at Boston Children's Hospital have developed 20 disease-specific stem cell lines for conditions such as Parkinson's Disease, Down Syndrome, and Muscular Dystrophy. These lines were created using the iPS technique and will be made available to researchers worldwide.
Researchers have created disease-specific stem cell lines for ten genetic disorders, including muscular dystrophy and Parkinson's disease. These lines will enable scientists to model human diseases in a laboratory setting, making it possible to study the development of various tissues relevant to these conditions.
Scientists at Harvard University have successfully created human stem cells from the skin cells of elderly ALS patients, paving the way for potential treatments. The breakthrough uses induced pluripotent stem (iPS) cells to differentiate into motor neurons, which can be studied in a lab dish to understand the disease process.
Researchers have created a new source of platelets that can be used for transfusions, addressing the risk of blood infections and improving clotting function. The innovative approach involves using a stem cell population already committed to becoming platelets, and blocking enzymes that cause clotting defects.
New research funded by the Economic and Social Research Council explores standards in stem cell research, balancing scientist autonomy with data comparability. The study suggests that standardizing practices could lead to automation technologies, but also raises concerns about exclusivity and robustness.
Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell-like state. The new method improves reprogramming efficiency and increases the total number of reprogrammed cells, enabling future studies on blood diseases.
Researchers have developed four unique human parthenogenetic stem cell lines that are HLA-homozygous, reducing the risk of provoking an immune reaction. These lines can serve as a renewable source of transplantable cells for treating genetic and degenerative diseases.
Wisconsin scientists have developed a culture system free of animal cells, growing two new human embryonic stem cell lines. The new lines survive for over seven months in the defined medium, showing promise for therapeutic use. However, further work is needed to understand chromosome stability during long-term culture.
Scientists discovered that some adult stem cells express characteristics of muscle and heart cells, suggesting they could be the 'footprints' of evolution. The researchers believe these cells may be incomplete or 'rudiments' of earlier embryonal differentiation processes.
Researchers found that most human embryonic stem cell lines exhibit gross genetic changes after a year to three years of growth in the lab. These changes can affect chromosome numbers, gene expression, and mitochondrial DNA sequences. The study highlights the need for close monitoring and further investigation into the effects of these...
Dr. Andras Nagy at Mount Sinai Hospital in Toronto has developed Canada's first embryonic stem cell lines, which hold promise for regenerating damaged tissues and treating various diseases. The lines will be freely available to Canadian scientists to research potential treatments.
Researchers have created patient-specific stem cell lines using somatic cell nuclear transfer, enabling the study of human disease in laboratory cells. The new cell lines displayed signs of immunological compatibility with patients' cells.
Researchers have developed a new way to culture human embryonic stem cells without using animal-derived materials, reducing the risk of contamination with pathogens. This breakthrough could lead to safer and more effective stem cell therapies for treating various diseases.
Researchers at WiCell Research Institute and University of Wisconsin-Madison develop method to eliminate need for feeder cells, simplifying culture of human ES cells. The new approach uses protein FGF2 to preserve undifferentiated state and reduce differentiation.
Researchers successfully coaxed human embryonic stem cells into antigen presenting cells that educate the immune system. These cells can control T cell responses, potentially reducing rejection rates for transplanted tissues.
The new cell lines, derived from private funds by Harvard University researchers, offer a robust and easy-to-handle alternative to existing human embryonic stem cells. The availability of these cell lines is expected to quicken the pace of discovery in stem cell biology, particularly in research related to type 1 diabetes.
Researchers have isolated stem cells from parthenogenic monkey eggs that can differentiate into various cell types, including neurons and tissues. These findings hold promise for developing an unlimited number of neurons for treating Parkinson's disease.
Researchers at Vanderbilt University Medical Center have discovered a gene, PTF1p48, that plays a crucial role in the development of the pancreas. The study found that p48 is required for the formation of both exocrine and endocrine cells, which could lead to the production of insulin-secreting cells from embryonic or other stem cells.
The Michael J. Fox Foundation awards a $10 million grant to Jeffrey Kordower, PhD, of Rush University Medical Center, to develop embryonic stem cell lines for Parkinson's disease treatment. The goal is to create dopaminergic cells that can be used in research and potentially lead to new treatments.
Researchers have successfully established a cell line that functions like adult human mammary stem cells, opening up new avenues for studying breast cancer and tissue regeneration. The discovery was made by Dr. Ole William Petersen and colleagues from the University of Copenhagen and Lawrence Berkeley National Laboratory.
Scientists have successfully generated primate stem cells from an unfertilized embryo through parthenogenesis, demonstrating the ability to produce various cell types, including midbrain dopamine neurons. This breakthrough could lead to new treatments for diseases such as Parkinson's and Huntington's, heart disease, and diabetes.